Moderna's personalized mRNA cancer vaccine, developed with Merck and combined with Merck's checkpoint drug Keytruda, showed positive results in a clinical trial measuring melanoma recurrence. The stock doubled in pre-market trading, reaching its highest level in two years. The trial marks the first time a personalized mRNA cancer vaccine has demonstrated efficacy in a late-stage study.
A double in pre-market is a rare, violent repricing of Moderna's pipeline value, and it pulls Merck into the move because the two companies share the commercial upside. Biotech ETFs with meaningful Moderna exposure will feel the lift, and the result revives investor interest in mRNA platforms beyond COVID, which had been the central bear case on Moderna for two years.
FDA review timeline for the melanoma vaccine candidate (no confirmed date yet). Merck Q2 earnings, ~July 2025, will include commentary on the Keytruda combination program. Watch for a formal Phase 3 trial readout date, which Moderna is expected to announce in the coming weeks.
Full analysis · Subscribers
The deep dive (bull case, bear case, and the data point that decides which side wins), the cause-and-effect chain behind the move, plain-English explainers for every block, and the live update timeline (2 updates so far).
Aggregated reads dozens of sources in five languages and turns the day into plain-English cards like this one.
Educational analysis of public information, not investment advice. Report an error · Corrections policy
← Today's brief